(University of Burgundy-Franche Comte, INSERM UMR1231)
Tumors are often characterized by severe inflammation and by the infiltration of immune cells. Our team is focusing its research on interrelations between cancer cells, inflammation and T CD4+ lymphocytes. We are also studying the influence of chemotherapy treatments on these cells. Our understanding of these mechanisms will lead to improvements in the treatments used in the management of patients with cancer.
Team: Ghiringhelli François (PU-PH) Contact
Our primary aim is to transfer as quickly as possible our discoveries from chemoimmunotherapy clinical trials. Two phase II trials based on our discoveries are now under way in a context of metastatic colon cancer.
Team: Vegran Frédérique (CR1) Contact
Our group is seeking to identify of molecular mechanisms able to confer antitumor properties to T CD4 Th17 and Th9 lymphocytes so as to use these cells in an anti-cancer cell-therapy strategy.
Team: Rébé Cédric (IB) Contact
The inflammasome is a complex that plays a major role in inflammation. Our objective is to better understand the function of the Nlrp3-type inflammasome in tumors.
Team: Caroline Truntzer (IB) Contact
We are developing of mathematical tools to use these massive data and to isolate the clinically pertinent information within this mass of information.
